update on hypertrophic and non compaction cardiomyopathy
TRANSCRIPT
![Page 1: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/1.jpg)
Update on Hypertrophic and Non Compaction Cardiomyopathy
Donna Mancini, MD
Professor of Medicine
![Page 2: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/2.jpg)
Left Ventricular Non- Compaction
• Intrauterine arrest of myocardial compaction w persistence of deep trabecular recesses in the endomyocardium
• Genetic Cardiomyopathy by AHA
• Unclassified cardiomyopathy by European Society
• Genetic heterogeneity--Autosomal dominant, X linked; mitochondrial
• Symptoms: CHF, Arrhythmias, clots
![Page 3: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/3.jpg)
![Page 4: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/4.jpg)
LVNC
• Prevalence in patients undergoing ECHO: 0.01-1.3%
• Genetics: Autosomal dominant; X linked; familial or sporadic (rare)
• Overlap w hypertrophic, congenital, dilated cardiomyopathies (common)
• 10 genes described: MHC7; Lamin, Tafazzin, troponin
• yield for genetic testing is 40-50%
![Page 5: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/5.jpg)
Clinical Presentation
• CHF 25%
• Abnormal Cardiac Exam 19%
• Abnl Echo 14%
• Abnormal EKG 16%
• Arrhythmia/Syncope 15%
• Sudden Cardiac arrest 2%
![Page 6: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/6.jpg)
![Page 7: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/7.jpg)
Diagnosis
• Prominent LV trabeculae
• Deep intertrabecular recesses
• Thin compacted layer
• ECHO or MRI
![Page 8: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/8.jpg)
ECHO Diagnosis
• ECHO Jenni Criteria:
– Thickened LV w 2 layers; thin compacted epicardial layer and thickened endocardial layer; numerous promenint trabeculations w deep recesses
– Ratio of non compacted to compacrted myocardium 2:1 at end systole parasternal short axis view
– Color Doppler flow in deep intertrabecular recesses
– Prominent Trabecular meshwork in LV apex or mid ventricular segments
![Page 9: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/9.jpg)
![Page 10: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/10.jpg)
MRI Criteria
• Trabeculated LV mass >20% of global LV mass
• End diastolic non compacted to compacted myocardial thickness of >2.3
• End systolic non compacted to compacted ratio >2.0
• Late gadolinium enhancement
![Page 11: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/11.jpg)
![Page 12: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/12.jpg)
Differential Diagnosis
• Athletes: 8% will have similar echo findings
• Hypertensive heart Disease
• Pregnancy
• Sickle Cell Anemia
• Cardiomyopathies –apical HCM, infiltrative (Fabry’s), endomyocardial fibrosis; congenital heart disease
• Black race
![Page 13: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/13.jpg)
Establish Diagnosis
• Similar finding in first degree relatives
• Absence of other conditions
• Symptoms
• Treatment of LVNC and CHF-same as CHF
• Treatment of LVNC and afib: low threshold for anticoagulation
• Treatment of LVNC and ICD standard indications for primary and secondary prevention
![Page 14: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/14.jpg)
Cardiac Compaction
• Very Rare
• Extensive overlap with other cardiomyopathies.
• Phenotypic variation
• Physiologic hypertrophy
![Page 15: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/15.jpg)
Hypertrophic Cardiomyopathy (HCM)
• Hypertrophic – an excessive thickening of the heart muscle
• Diastole
– impaired diastolic filling, filling pressure
• Systole
– dynamic outflow tract gradient
• Myocardial ischemia
– muscle mass, filling pressure, O2 demand
– abnormal intramural coronary arteries
– systolic compression of arteries
![Page 16: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/16.jpg)
HCM vs. Normal
![Page 17: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/17.jpg)
Who Does HCM affect?
• 1 in 500 people (most common genetic cardiovascular disease) – Incidence is about 0.2% to 0.5% of general population.
• An estimated 600,000 to 1.5 million Americans have HCM.
• HCM can present at anytime in any age of life
• Most people are not aware they have HCM because symptoms can go unnoticed and most people with the disease live healthy, normal lives
![Page 18: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/18.jpg)
Genetics • Autosomal dominant trait
– Mutations in genes that encode one of the sarcomere proteins including • Beta-cardiac myosin heavy chain (the first gene
identified),
• Cardiac actin,
• Cardiac troponin T,
• Alpha-tropomyosin,
• Cardiac troponin I,
• Cardiac myosin-binding protein C, and
• Myosin light chains.
– >400 mutations in these genes.
– Frequency • 45% of mutations occur in β myosin heavy chain gene
• 35% involve cardiac myosin binding protein C gene.
![Page 19: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/19.jpg)
![Page 20: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/20.jpg)
Variants of HCM: Most common location: subaortic , septal, and ant. wall.
• Asymmetric hypertrophy (septum and ant. wall): 70 %.
• Basal septal hypertrophy: 15- 20 %.
• Concentric LVH: 8-10 %.
• Apical or lateral wall: < 2 % (25 % in Japan/Asia): characteristic giant T-wave inversion laterally & spade-like left ventricular cavity: more benign.
![Page 21: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/21.jpg)
65% 35%
10%
Types of HCM
ASH
Symmetric
Apical
![Page 22: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/22.jpg)
HOCM
Mitral valve presses against septum
MR
![Page 23: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/23.jpg)
LVOT Obstruction
-Septal bulge
-Mitral valve is large and
slack
~2/3 of HCM pts have
abnormal MV
-Mitral valve papillary
muscles and leaflets are
anteriorly positioned
Sherrid MV Progress in Card. Diseases 2012
Klues HG et al Circulation 1992
![Page 24: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/24.jpg)
Prevalence of LVOT Obstruction
Rest obstruction
≥30mmHg
37%
With exercise
33%
Non obstructive
30%
70%
Maron, M et al Circulation 2006
Sensitivity
of Valsalva 40%
![Page 25: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/25.jpg)
![Page 26: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/26.jpg)
Echocardiography in Hypertrophic Cardiomyopathy
• Define pattern of hypertrophy asymmetric; concentric • Assess systolic function • Assess diastolic function • Quantitate obstruction • Assess concomitant mitral regurgitation • Risk stratify • Differentiate from athlete’s heart • Differentiate from restrictive CM • Help guide myomectomy and alcohol ablation
![Page 27: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/27.jpg)
Mitral Valve assessment
• Because the anterior leaflet motion is greater than that of the posterior leaflet during SAM an interleaflet gap occurs
• The jet of mitral regurgitation is directed laterally and posteriorly and predominates during mid and late systole
• Not all MR in HCM is due to SAM
• Intrinsic disease
![Page 28: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/28.jpg)
Presentation of HCM
![Page 29: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/29.jpg)
Causes of Sudden Death in Young Athletes
![Page 30: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/30.jpg)
Prognosis – Sudden Cardiac Death
• Adults - 2-3% SCD per year
• Adolescents - 4-6% SCD per year
• Infants (less than 1 yr old), mortality = 50%
![Page 31: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/31.jpg)
Risk Factors for SCD
• Massive LVH (e.g > 30 mm)
• Family history of sudden death
• Unexplained/recurrent syncope
• Nonsustained VT (Holter Monitoring)
• Drop in blood pressure during exercise
Br Heart J 1994; 72:S13
•? Genetic mutations prone to SCD •? Gadolinium enhancement on MRI >20% •Risk models to estimate rate of SD and guide ICD placement
![Page 32: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/32.jpg)
High Risk Genes
• Beta-myosin heavy chain (MYH7) – R403Q
– R453C
– G716R
– R719W
• Cardiac troponin T gene (TNNT2) – R92W
• Only 3 of 293 (<1%) were positive for these mutations
J Am Coll Cardiol 2002;39:2042– 8)
![Page 33: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/33.jpg)
Differential Diagnosis:
HCM • Can be asymmetric
• Wall thickness: > 15 mm
• LA: > 40 mm
• LVEDD : < 45 mm
• Diastolic function: always abnormal
Athletic heart • Concentric & regresses
• < 15 mm
• < 40 mm
• > 45 mm
• Normal
![Page 34: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/34.jpg)
Natural History/Prognosis
• Annual mortality 3% in referral centers, probably closer to 1% for all patients
• Risk of SCD higher in children may be as high as 6% per year
– Majority have progressive hypertrophy
• Clinical deterioration usually is slow
• Progression to DCM occurs in 10-15%
![Page 35: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/35.jpg)
Natural History Aging is Good in HCM
Maron B et al Circulation 2000
Maron B et al Circulation 2013
Cohort >60 years
![Page 36: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/36.jpg)
Obstruction and Prognosis Obstruction is not good
Maron MS et al NEJM 2003
![Page 37: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/37.jpg)
Atrial Fibrillation Poor Prognostic Factor
20% of patients
• 4x the risk of general population
• Amiodarone
• Coumadin
• CHADS score not validated
in this cohort
• RFA/ AVN ablation
Maron BJ, et al. J Am Coll Cardiol 2002
Olivotto I, et al Circulation 2001
![Page 38: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/38.jpg)
Sudden death Heart failure “ Burned out HCM”
AF&
Stroke
Treatment
ICD
Rx Surgery Septal
ablation
Transplant
Rx RFA
Maze
![Page 39: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/39.jpg)
Management
• Lifestyle Modifications
• Medications
– Beta-adrenergic blockers
– Calcium antagonist
– Disopyramide
– Amiodarone, Sotolol
• DDD pacing
• Surgery
– Myectomy/Septal Ablation
– Mitral Valve Repair/Replacement
– Heart Transplantation
![Page 40: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/40.jpg)
Obstructive HCM with SXS
Verapamil
+
Disopyramide
PM with short AV delay
Septal myectomy or ablation
Symptoms Anterior MV leaflet
>33mm Rest
Gradient>90mmHg
Symptoms
Sherrid MV Progress in Cardiovascular dz. 2012
BB
![Page 41: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/41.jpg)
Beta Blockers
• First line therapy, due to negative inotropy
• Reduces exercise induced gradient, not expected to reduce resting gradients
• Improves exertional dyspnea and chest pain
• Titrate to HR 60-65 • Favor: Metoprolol, Bisoprolol, Atenolol • Avoid: Carvedilol and Labetalol
Flamm Circulation 1968
Stenson Am J Cardiol 1973
Cabrera Bueno Int J Cardiol 2007
![Page 42: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/42.jpg)
Calcium Channel Blockers: Verapamil / Diltiazem
• Lower inotropic effect than beta blockers
• Usually reserved for patients with mild to moderate obstruction and/or contraindications to BB therapy
![Page 43: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/43.jpg)
Disopyramide
Pollick C NEJM 1982
• Negative Inotropy
• Blocks Na and Ca channels
• Most effective in
decreasing resting gradient
![Page 44: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/44.jpg)
Transplant
-NYHA Class III/IV symptoms refractory to all medical
and surgical options.
-Low LVEF is not absolutely required
Maron B Circ HF 2010
Kato TS AJC 2012
![Page 45: Update on Hypertrophic and Non Compaction Cardiomyopathy](https://reader034.vdocuments.mx/reader034/viewer/2022043020/626c1b991cc3e22d634825b8/html5/thumbnails/45.jpg)
Conclusion
• HCM is a common genetic cardiomyopathy
• Prevention of SD questions remain as to timing of ICD
• Screening of first degree relatives
• Expanding medical and surgical options for treatment—Septal ablation for young patients as long term efficacy of alcohol ablation is unknown